<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003792</url>
  </required_header>
  <id_info>
    <org_study_id>BAYUMC-098004</org_study_id>
    <secondary_id>CDR0000066935</secondary_id>
    <secondary_id>NCI-T98-0054</secondary_id>
    <nct_id>NCT00003792</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Dendritic Cell Immunotherapy of Metastatic Melanoma - A Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Health Care System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's white blood cells and melanoma cells may make the
      body build an immune response and kill tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who
      have metastatic melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the safety and tolerability of antigen pulsed dendritic cell therapy
      in patients with metastatic melanoma. II. Perform serial analysis of T cell and B cell
      function in these patients after this treatment. III. Determine objective response and
      response duration in these patients after this treatment.

      OUTLINE: Patients receive filgrastim (G-CSF) subcutaneously (SQ) on days 1-6, then undergo
      leukapheresis for 2-3 days, beginning on day 6. Mononuclear cells are selected for CD34+
      cells in the laboratory, made into dendritic cells, and then pulsed with MART-1, gp100,
      tyrosinase, MAGE-3 peptides and flu matrix. These antigen pulsed dendritic cells (ApDCs) are
      used for vaccinations. Prior to vaccination, ApDCs are mixed with MART-1, gp100, tyrosinase,
      MAGE-3, and flu matrix. Patients receive this dendritic cell vaccine mixture SQ every 2 weeks
      for 4 priming doses. Patients receive 4 boost vaccinations SQ at 2 months, 5 months, 9
      months, and 15 months following the last priming vaccination. Patients are followed monthly
      for 2 years.

      PROJECTED ACCRUAL: A total of 28 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>flu matrix peptide p58-66</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant MAGE-3.1 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tyrosinase peptide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven metastatic melanoma Measurable disease
        HLA-A2 01 phenotype No active CNS or hepatic metastases

        PATIENT CHARACTERISTICS: Age: 18 to 80 Performance status: Karnofsky 80-100% Life
        expectancy: Not specified Hematopoietic: Normal CD4 and CD8 T cell numbers by flow
        cytometry Lactic dehydrogenase less than 2 times normal Hepatic: No viral hepatitis Renal:
        Not specified Cardiovascular: No prior venous thrombosis, angina pectoris, or congestive
        heart failure Pulmonary: No prior asthma Immunologic: Positive intradermal skin test for
        mumps, histoplasmosis, or streptokinase antigen Immunoglobulin levels normal No prior
        autoimmune disease (lupus erythematosus, rheumatoid arthritis, or thyroiditis) No allergy
        to tetanus toxoid or influenza vaccine No sensitivity to E. coli drug preparations Other:
        Not pregnant or nursing Fertile patients must use effective contraception HIV negative No
        active infection

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior interferon At
        least 8 weeks since prior interleukin-2 Chemotherapy: No more than 3 prior courses of
        cytotoxic chemotherapy At least 8 weeks since prior chemotherapy Endocrine therapy: No
        concurrent corticosteroids Radiotherapy: Not specified Surgery: Not specified Other: No
        other concurrent immunosuppressive agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph W. Fay, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Baylor Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2004</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

